Search Results - "Sankar, Neil"

Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark by Ehrenstein, Vera, Andersen, Søren L, Qazi, Ibrahim, Sankar, Neil, Pedersen, Alma B, Sikorski, Robert, Acquavella, John F

“…Tenosynovial giant cell tumor (TGCT) is a rare benign proliferative and inflammatory disease arising from synovia of joints, bursae, or tendon sheaths. We…”
Get full text

A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS) by Sankhala, Kamalesh Kumar, Blay, Jean-Yves, Ganjoo, Kristen N., Italiano, Antoine, Hassan, Andrew Bassim, Kim, Tae Min, Ravi, Vinod, Cassier, Philippe Alexandre, Rutkowski, Piotr, Sankar, Neil, Qazi, Ibrahim, Sikorski, Robert S., Collins, Helen, Zhang, Charlie, Shocron, Ellyn, Gelderblom, Hans

“…Abstract only 11078 Background: TGCTis a proliferative, neoplastic joint disease that presents as single nodule (local) or multiple nodules (diffuse D-TGCT)…”
Get full text

Abstract CT137: A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors by Geller, James I., Brown, Dennis, Bacha, Jeffrey, Sankar, Neil, Kanekal, Sarath, Leggas, Mark, Wagner, Lars

“…Background: Ewing's sarcoma (EWS) is the second most common malignant bone tumor affecting children, adolescents and young adults. Intravenous irinotecan…”
Get full text

A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors by Bacha, Jeffrey A., Brown, Dennis, Geller, James I., Oesterheld, Javier E., McManus, Meghann, Kanekal, Sarath, Leggas, Markos, Lopez, Lorena, Sankar, Neil, Yam, Noymi, Wagner, Lars M.

“…TPS10073 Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer and also used off-label to treat a…”
Get full text

Abstract P081: In vitro activity and efficacy of novel dual PARP-HDAC inhibitors by Truong, Sarah, Ghaidi, Fariba, Ramos, Louise, Joshi, Jay, Brown, Dennis, Sankar, Neil, Langlands, John, Bacha, Jeffrey, Shen, Wang, Daugaard, Mads

“…Introduction: Inhibition of poly adenosine diphosphate-ribose polymerase (PARP) is an effective treatment strategy against tumors with homologous recombination…”
Get full text

A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors by Brown, Dennis, Bacha, Jeffrey A., Geller, James I., Thompson, Patrick A., Oesterheld, Javier E., Kanekal, Sarath, Leggas, Markos, Lopez, Lorena, Sankar, Neil, Yam, Noymi, Wagner, Lars M.

“…TPS10063 Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also widely used…”
Get full text

CTNI-75. A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS by Brown, Dennis, Bacha, Jeffrey, Wagner, Lars, Leggas, Markos, Kanekal, Sarath, Lopez, Lorena, Sankar, Neil

“…Tumors of the brain and of the central nervous system (CNS) are the most common solid tumors in children. Intravenous irinotecan hydrochloride (IRN-IV) is…”
Get full text

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer by Bacha, Jeffrey A., Brown, Dennis, Kanekal, Sarath, Nisbet, Ian, Sankar, Neil, Shen, Wang, Wheeler, Helen, Skoff, Kathy, Wang, Zhen Zhong

“…Background: ErbB receptor tyrosine kinases: EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) are part of a complex network activating signaling…”
Get full text

A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors by Luke, Jason J., Kennedy, Laura Carpin, Sankar, Neil, Menzies, Alexander M., van Akkooi, Alexander Christopher Jonathan, Gonzalez, Maria, Urban, Julie, Gill, Mini, Atkins, Cynthia M., Quiñones, Julian, Miller, Brian, Duhamel, Alison A., Sowell, Ryan T., Nambiar, Prashant R, Kitada, Tasuku, Piha-Paul, Sarina A., Sankhala, Kamalesh, Long, Georgina V.

“…TPS2696 Background: STX-001 is a multi-mechanistic lipid nanoparticle encapsulated synthetic self-replicating mRNA, engineered to express the IL-12 cytokine…”
Get full text

CTNI-08. A PHASE 1–2 CLINICAL TRIAL OF EO1001, A NOVEL IRREVERSIBLE PAN-ErbB INHIBITOR WITH PROMISING BRAIN PENETRATION by Wheeler, Helen, Bacha, Jeffrey, Brown, Dennis, Kanekal, Sarath, Sankar, Neil, Nisbet, Ian, Skoff, Kathy, Shen, Wang, ZhenZhong, Wang, Pedersen, Harry

“…Mutations causing errant ErbB activation are implicated in many cancers, including tumors correlated with high incidence of CNS metastasis. ErbB family member…”
Get full text

A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma by Kang, Hyunseok, Ho, Alan Loh, Muzaffar, Jameel, Bowles, Daniel W., Kim, Sung-Bae, Ahn, Myung-Ju, Hanna, Glenn J., Worden, Francis P., Yun, Tak, Norton, Steven, Sankar, Neil, Keam, Bhumsuk

“…Abstract only TPS6597 Background: Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy, also found in other secretory gland sites…”
Get full text

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment by El-Khoueiry, Anthony B., Tchekmedyian, Nishan, Sanborn, Rachel E., Peguero, Julio Antonio, Pulver, Kerry, Dembla, Vikas, Thomas, Jacob Stephen, Chiang, Gary Gene, Densel, Mark, Sankar, Neil, Worland, Stephen Theodore, Gleich, Lyon L., Sikorski, Robert S.

“…Abstract only 3112 Background: Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response…”
Get full text

A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors by Voskoboynik, Mark, Richardson, Gary Edward, Mileshkin, Linda R., McNeil, Catriona M., Horvath, Lisa, Benedetti, Fabio M., Choy, Gavin S., Sankar, Neil, McCurry, Shelly, Zhang, Xiaoling, Gao, Min, Shah, Ajit K., Millward, Michael

“…Abstract only e15125 Background: APL-501 is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1). APL-501 is being evaluated in patients…”
Get full text

CTNI-01. A PHASE 1-2 CLINICAL TRIAL OF EO1001 (APL-122), A NOVEL IRREVERSIBLE PAN-ERBB INHIBITOR WITH PROMISING BRAIN PENETRATION by Frentzas, Sophia, Richardson, Gary, Bacha, Jeffrey, Kanekal, Sarath, Sankar, Neil, Shen, Wang, Redkar, Sanjeev, Lai, Chinglin, Yu, Peony, Nisbet, Ian, Skoff, Kathy, Wheeler, Helen, Pedersen, Harry, Zhong, Wang Zhen, Brown, Dennis

“…CNS metastases are a prominent driver of cancer morbidity and mortality, especially as targeted therapies have improved systemic outcomes. Mutations in the…”
Get full text

Abstract CT058: A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors by Geller, James, Thompson, Patrick, Oesterheld, Javier, Kim, Aerang, McManus, Meghann, Bacha, Jeffrey, Brown, Dennis M., Leggas, Markos, Kanekal, Sarath, Sankar, Neil, Lopez, Lorena, Yam, Noymi, Wagner, Lars M.

“…Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. An off-label regimen of IRN-IV administered…”
Get full text

Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer by Chawla, Sant P., Chua, Victoria S., Gordon, Erlinda Maria, Moradkhani, Ania, Kim, Katherine, Quon, Doris, Wong, Steven, Sumner, Robert, Mac, Virginia, Huang, Raymond, Wang, Kelly, Kim, Jiyeun, Kim, Bumjin, McGinn, Arlo N., Park, Cheol Hee, Houston, Scott, Sankar, Neil

“…Abstract only 18 Background: Due to their immuno-modulatory effects, anti-angiogenic drugs have been clinically investigated in combination with anti-PD-1…”
Get full text

Abstract CT135: A pilot clinical study of orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors by Bacha, Jeffrey, Brown, Dennis, Kanekal, Sarath, Sankar, Neil, Lopez, Lorena, Yam, Noymi, Wagner, Lars, Geller, James, Leggas, Markos, Thompson, Patrick, Osterheld, Javier

“…Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also used off-label to treat a…”
Get full text

Abstract A037: Exploring the therapeutic effectiveness of EO3001 in the treatment of clear cell ovarian cancers with ARID1A mutations by Ding, Yuchen, Li, Lucy Yuqin, Zhang, Joyce Yuhan, Kabeer, Farhia, Lam, TszYin, Kalantari, Forouh, Bacha, Jeffrey, Brown, Dennis, Kanekal, Sarath, Sankar, Neil, Lizardo, Michael, EL-Naggar, Amal, Huntsman, David

“…Introduction: Clear Cell Ovarian Cancer (CCOC) is an inherently chemoresistant subtype of ovarian cancer, accounting for approximately 10% of all epithelial…”
Get full text

Abstract A024: In vitro efficacy of a novel dual PARP-HDAC inhibitor in ewing sarcoma by Truong, Sarah, Zhai, Beibei, Ghaidi, Fariba, Ramos, Louise, Joshi, Jay, Brown, Dennis, Sankar, Neil, Langlands, John, Bacha, Jeffrey, Shen, Wang, Sorensen, Poul, Daugaard, Mads

“…Introduction: Inhibition of poly-adenosine diphosphate-ribose polymerase (PARP) is an effective therapy against cancers with DNA damage repair (DDR)…”
Get full text

Abstract CT256: A pilot clinical study of VAL-413 (Orotecan®, oral irinotecan HCl) in patients with recurrent pediatric solid tumors by Geller, James, Thompson, Patrick, Oesterheld, Javier, Brown, Dennis M., Bacha, Jeffrey, Kanekal, Sarath, Lopez, Lorena, Leggas, Markos, Sankar, Neil, Yam, Noymi, Wagner, Lars M.

“…Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer. IRN-IV is also widely used off-label for a range of…”
Get full text